publication date: Sep. 16, 2016

NCI Director’s Report

Lowy: RPG Funding Increased by $100M From 2013 to 2015—150 More Grants Funded

By Tessa Vellek

Research Project Grant funding at NCI has increased 25 percent, from $400 million in 2013 to $500 million in 2015, NCI Acting Director Douglas Lowy said to the National Cancer Advisory Board Sept. 7.

NCI’s fiscal 2016 budget is $5.21 billion, an increase of $260.5 million over fiscal 2015. This represents the  first time in about three years that funding for the institute has recovered to above pre-sequestration levels.

The grant success rates have stayed relatively flat since 2013 and the average dollar amount per award has gone up slightly, but the number of awards has increased from approximately 1,050 awards to about 1,200 in the same period.

New and established investigators benefited from the increase in the number of grants, Lowy said.

The RPG pool needs an additional $300 million between now and fiscal 2022 to maintain current award rates for Type 1 and Type 2 grants, Lowy said. This comes up to about $80 million for fiscal 2017.

“One of the issues that we have noted is that the number of program project grants that are actually awarded has fallen off to some degree over the last few years,” Lowy said at the NCAB meeting. “We are committing ourselves to redressing that by encouraging our colleagues extramurally to apply for program project grants, and we are going to be endeavoring to make more awards of program project grants than we have in the past.

“We recognize that, inadvertently, we have been making fewer PO1 awards than in the past. We have been sending out a signal to the extramural community that we … Continue reading 42-34 Lowy: RPG Funding Increased by $100M From 2013 to 2015—150 More Grants Funded

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.